An Alternate Future

We exist to create an alternate future for people with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people living with these debilitating diseases.

First-in-class therapies to treat neurodegenerative disease

Alterity is developing first-in-class therapies to treat neurodegenerative disease. Our lead drug candidate, ATH434, has demonstrated efficacy in several animal models of Parkinsonian disorders and is being evaluated in clinical trials.

Our therapies

Latest News

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

May 30, 2023

Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023

May 19, 2023

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

May 10, 2023